Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 357

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 357
---
  
 Other        
 Unobservable 
 Inputs       
 (Level 3)    |   |
|:-------------------|:----|:------|--:|:----|:----------|----------:|:----|:------------|:--|:----|:-------------|:--|
| Money Market Funds |     |       | 1 |     | $         | 8,436,311 |     |             | — |     |              | — |

Note 9 — Subsequent Events The Company evaluated subsequent events and transactions that occurred up to the date the financial statements were issued. Based upon this review, other than described below, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements. On January 3, 2024, the Company held a special meeting of stockholders (the “Third Special Meeting”). At the Third Special Meeting, the Company’s stockholders approved an amendment (the “Third IMTA Amendment”) to the IMTA, as amended by the First IMTA Amendment and the Second IMTA Amendment, and an amendment (the “Third Charter Amendment”) to the Charter, as amended by the First Charter Amendment and the Second Charter Amendment, to extend the business combination period up to three times for one month each time (the “Third Extension”). In connection with the approval of the Third Extension, the Sponsor deposited $ 22,600in the Trust Account, and holders of 11,625Public Shares exercised redemption rights requiring the Company to make a series of payments of an aggregate of $ 128,133for an aggregate $ 11.02per redeemed share. As a result, following satisfaction of such redemptions, the Company had 6,234,582shares of Class A common stock outstanding, of which (i) 753,332were Public Shares, which were entitled to receive a pro rata portion of the remaining funds in the Company’s Trust Account in connection with its initial Business Combination, a liquidation or certain other events, (ii) 4,596,250were Class A common stock issued upon the conversion of an equal number of shares of the Class B common stock, which did not have redemption rights, and (iii) 885,000were Private Placement Shares, which did not have redemption rights. As a result of the deposit described above, such payments and accrual of interest, the balance in the trust account as of the last extension payment was approximately $ 8.4million. F-45 PHOENIX BI